Medical Devices

100 VCs and 14 funds investing in Medical Devices

VCs investing in Medical Devices

Alex Morgan

Partner

88%

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

IncubationPre-SeedSeed

Arielle Rothman

Investor

87%

BoxGroup

Check: No reliable Arielle-specific check size is public. BoxGroup describes itself as an earliest-stage investor, but founders should confirm current round fit and allocation directly rather than relying on third-party range estimates.

Arielle invests within BoxGroup's broad earliest-stage mandate. Her differentiated documented context is technical and translational: Harvard bioengineering research, founding a postpartum medical-device project, product work in fertility AI and neuromodulation, mechanical engineering at a bioelectronic-medicine startup, and consulting at BCG. This supports a credible ability to evaluate user need, clinical workflow, product design, manufacturing, regulatory planning and commercialization in technical health businesses. It does not establish an exclusive healthcare mandate or a personally published investment thesis.

Pre-seedSeedEarliest-stage company formation

Aristos Doxiadis

Partner Emeritus

85%

Big Pi Ventures

Check: No current personal check range: Aristos is Partner Emeritus and an official 2025 biography says he is not involved with Big Pi's later funds. Big Pi's current platform range is €0.5M–€30M across funds, but should not be attributed to him.

Aristos' historical investment lens combines strong technology, team, and market position with realistic commercialization targets. He favors research-based ventures that can bridge academia and industry, secure early adopters beyond a small home market, and use seed or Series A capital to build enough traction for international follow-on funding. His long private-equity career also brings attention to governance, business fundamentals, and social or economic impact.

SeedSeries AEarly Stage

Charlie Plauche

Managing Director

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Charlie Plauche is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Kevin Haley

Associate

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Kevin Haley is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Eric Engineer

General Partner

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Eric Engineer is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Nicole Bentz

Vice President

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Nicole Bentz is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Joe Curry

Principal

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Joe Curry is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Oscar Moralez

Founder and Managing Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Oscar Moralez invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Anthony Marfisi

Associate

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Anthony Marfisi is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Wayne Wallace

Co-Founder and Partner

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Wayne Wallace invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Will Omberg

Senior Associate

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Will Omberg is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Kathryn Deebel

Director of Platform & Network

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Kathryn Deebel is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Shelley Graves

Controller

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Shelley Graves is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Ariel MacTavish

Venture Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Ariel MacTavish invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

J. Carter McNabb

Managing Partner

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

J. Carter McNabb contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Audrey Beckman

Partner and Chief Innovation Officer

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Audrey Beckman invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Dick Aderman

Studio Director

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Dick Aderman is listed in a Studio Director capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Britney Hamberg

Principal, Investor Relations & Operations

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Britney Hamberg contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Todd R. Lugar

Controller and HR Lead

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Todd R. Lugar is listed in a Controller and HR Lead capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Tony Petrucciani

Partner and Chief Financial Officer

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Tony Petrucciani is listed in a Partner and Chief Financial Officer capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Bill Trainor

Co-Founder and Partner

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Bill Trainor invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Britney Byrd

Analyst, Finance

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Britney Byrd contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Ally Thill

Project Leader

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Ally Thill is listed in a Project Leader capacity at Boomerang Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves that role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedSeries A

Dan Clark

Venture Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Dan Clark invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

David Helmer

Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

David Helmer invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Eric Beier

Partner and Chief Medical Officer

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Eric Beier invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Tejas Vijh

Associate

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Tejas Vijh invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Liz Todia Zambory

Principal

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Liz Todia Zambory invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Will Brune

Senior Associate

80%

Mutual Capital Partners

Check: Mutual Capital Partners does not publish a standard current check-size range on its official site.

Will Brune invests or supports investments through Mutual Capital Partners's published strategy: Partner with healthcare IT and medical-device companies outside major technology centers that have strong teams, reference customers, meaningful revenue and attractive margins.

Early StageGrowth

Alain Horvais

Partner, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Alain Horvais as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Amanda Gett

Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Amanda Gett as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Robert Heimann

Managing Partner

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Robert Heimann contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Rurik “Rik” Vandevenne

Managing Partner

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Rurik “Rik” Vandevenne contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Patrick Dunnigan

Partner

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Patrick Dunnigan contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Adrienne Vannarsdall

CFO

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Adrienne Vannarsdall contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Parag Rathi

Principal

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Parag Rathi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Vitaly Goldfeder

Principal

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Vitaly Goldfeder contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Sonny Guilhem

Senior Financial Controller

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Sonny Guilhem as Senior Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Dana Tanenbaum

Controller

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Dana Tanenbaum contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Paul Axelrod

Vice President

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Paul Axelrod contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Scott Steever

Vice President

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Scott Steever contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Ryan Moeller

Vice President

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Ryan Moeller contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Marcus Fields

Senior Associate

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Marcus Fields contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Saloni Rai

Analyst, Investor Relations

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Saloni Rai contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Kushal Modi

Analyst, Investments

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Kushal Modi contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Federica Porcu

Financial Controller and ESG Manager

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Federica Porcu.

Federica Porcu serves Panakès Partners as Financial Controller and ESG Manager. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Early StageGrowth Stage

Kaity Lynch

Manager of Administration

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Kaity Lynch contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Jim Adox

Managing Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Jim Adox invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Scott Button

Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Scott Button invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Paul Weiss

Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Paul Weiss invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

David Arnstein

Partner and Chief Financial Officer

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

David Arnstein is listed in a Partner and Chief Financial Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

John Neis

Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

John Neis invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Joe Amaral, MD

Chief Medical and Scientific Officer

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Joe Amaral, MD is listed in a Chief Medical and Scientific Officer capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Jenni Le

Principal

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Jenni Le invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Margaret Kaczor Andrew

Venture Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Margaret Kaczor Andrew invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Cheryl R. Blanchard, PhD

Executive in Residence

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Cheryl R. Blanchard, PhD invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Shelly Lanning

Venture Partner

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Shelly Lanning invests or supports investments through Clarevia's published strategy: Back visionary healthcare entrepreneurs and breakthrough ideas that can improve patient lives, from therapeutic and device innovation to new care solutions.

SeedEarly StageGrowth

Becky Hoerman

Controller

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Becky Hoerman is listed in a Controller capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Linda Olson

Office Manager

80%

Clarevia

Check: Clarevia does not publish a standard current check-size range on its official site.

Linda Olson is listed in a Office Manager capacity at Clarevia. No person-specific investment thesis is published for this role; the firm's mandate is included only as shared context.

SeedEarly StageGrowth

Benjamin Belot

Partner, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Rémi Droller

Managing Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Rémi Droller as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Daniel Fleming

Managing Partner

80%

RC Capital

Check: RC Capital does not publish a standard check-size range on its current official website.

Daniel Fleming contributes to RC Capital's published strategy: Build high-potential healthcare companies that improve care delivery, patient experience and outcomes across devices, services and healthcare IT.

Growth StageLower Middle Market

Alex Shandiz

General Partner

80%

Boomerang Ventures

Check: Boomerang Ventures does not publish a standard current check-size range on its official site.

Alex Shandiz invests or supports investments through Boomerang Ventures's published strategy: Build and invest in connected-health companies improving care quality, access, delivery, efficiency and patient experience, with particular attention to Midwest opportunities.

Pre-SeedSeedSeries A

Thierry Laugel

Managing Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Thierry Laugel as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Peter Neubeck

Partner Germany, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Peter Neubeck as Partner Germany, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Daniel Parera

Partner Germany, Growth Opportunities

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Daniel Parera as Partner Germany, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Philippe Peltier

Partner, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Philippe Peltier as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Jean-François Rivassou

Partner, Growth Opportunities

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Jean-François Rivassou as Partner, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Hadrien Bouchez

Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Hadrien Bouchez as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Laura Achach

Associate, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Laura Achach as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Samantha Zennou

Associate, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Samantha Zennou as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Florence de Coorebyter

Associate, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Florence de Coorebyter as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Anna Tchorzewska

Associate, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Anna Tchorzewska as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Maylis Deschamps

Associate, Growth Opportunities

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Maylis Deschamps as Associate, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Louise-Marie Rakotoarison

Analyst, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Louise-Marie Rakotoarison as Analyst, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Muriel Domine

Secretary General, Head of Compliance & Legal

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Muriel Domine as Secretary General, Head of Compliance & Legal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Cyril Bedran

Financial Director

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Cyril Bedran as Financial Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Aaron Perman

General Partner

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Aaron Perman is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Ornella Gomis

Financial Controller

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Ornella Gomis as Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Steffi Minga

Office Manager

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Steffi Minga as Office Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Fatima Boubnad

Management Assistant

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Fatima Boubnad as Management Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Fabrizio Landi

Founder and Managing Partner

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Fabrizio Landi.

Fabrizio Landi works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Alessio Beverina

Founder and Managing Partner

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Alessio Beverina.

Alessio Beverina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Diana Saraceni

Founder and Managing Partner

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Diana Saraceni.

Diana Saraceni works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Barbara Castellano

Partner

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Barbara Castellano.

Barbara Castellano works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Rob Woodman

Partner

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Rob Woodman.

Rob Woodman works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Marco Sardina

Scientific Partner

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Marco Sardina.

Marco Sardina works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Alessio Piuma

Principal

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Alessio Piuma.

Alessio Piuma works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Andrea Ballerini

Investment Manager

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Andrea Ballerini.

Andrea Ballerini works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Giacomo Piccinini

Investment Manager

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Giacomo Piccinini.

Giacomo Piccinini works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Annalisa Coraducci

Senior Analyst

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Annalisa Coraducci.

Annalisa Coraducci works on Panakès Partners's strategy to back ambitious early-stage life-sciences teams developing products that address important medical needs and improve patient and caregiver outcomes. The firm does not publish a narrower personal mandate on the cited roster.

Early StageGrowth Stage

Lorenzo Giordano

Chief Financial Officer

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Lorenzo Giordano.

Lorenzo Giordano serves Panakès Partners as Chief Financial Officer. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Early StageGrowth Stage

Paola Crovato

Office and Deal Flow Manager

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Paola Crovato.

Paola Crovato serves Panakès Partners as Office and Deal Flow Manager. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Early StageGrowth Stage

Brian R. Smith

Managing Director

80%

S3 Ventures

Check: $500K-$15M+ initial check range published by S3 Ventures; no person-specific range is disclosed.

Brian R. Smith is part of S3 Ventures's current team. No narrower person-specific mandate is published, so this profile uses the firm's official strategy: Lead Seed, Series A, and Series B rounds in business software and healthcare technology using patient single-LP capital and hands-on operating resources.

SeedSeries ASeries B

Michela Barcella

Network and Portfolio Talent Advisor

80%

Panakès Partners

Check: Panakès Partners does not publish a standard current check-size range on its official site.. No person-specific check range is inferred for Michela Barcella.

Michela Barcella serves Panakès Partners as Network and Portfolio Talent Advisor. The official sources do not publish a separate personal investment thesis, so the profile retains the firm's stated strategy without attributing it personally.

Early StageGrowth Stage

Karel Kubias, MBA

Founding Partner

80%

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Karel Kubias, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

Company CreationPre-SeedSeed

Ivan Vohlmuth

Founding Partner

80%

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Ivan Vohlmuth invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

Company CreationPre-SeedSeed

Barbora Šumová, Ph.D.

Partner

80%

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Barbora Šumová, Ph.D. invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

Company CreationPre-SeedSeed

Tomáš Maršálek, MBA

Founding Partner

80%

i&i Bio

Check: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.

Tomáš Maršálek, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.

Company CreationPre-SeedSeed

Funds focused on Medical Devices